EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Scleromyxedema Managed With High‐Dose Intravenous Immunoglobulin and Bortezomib–Dexamethasone: A Case Report

Darren Wijaya iD, Zachary Hanson, Eric K Lau, Mojtaba Akhtari

Case Reports in Oncological Medicine · 2026-01 · 2026 (1)

DOI: 10.1155/crom/3773160 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncological Medicine, online erschienen am 26.02.2026. Verfasst von Darren Wijaya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Loma Linda University Health, Loma Linda, California, USA, lluh.org. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Scleromyxedema is a rare, chronic cutaneous mucinosis marked by widespread waxy papules and potential extracutaneous involvement. This case report discusses the management of a 48‐year‐old female diagnosed with scleromyxedema, who initially partially responded to high‐dose intravenous immunoglobulin (HDIVIG) therapy. After partial relapse, she was induced with bortezomib, a proteasome inhibitor, and dexamethasone, achieving significant clinical improvement. Long‐term maintenance with IVIG was utilized to prevent recurrence of symptoms. This case highlights the effectiveness of both HDIVIG and bortezomib–dexamethasone dual therapy as viable treatment options for scleromyxedema, emphasizing the importance of maintenance therapy to prevent relapse.

Autor:innen und Institutionen

  • Department of Internal Medicine, Loma Linda University Health, Loma Linda, California, USA, lluh.org.
  • Division of Medical Oncology and Hematology, Loma Linda University Health, Loma Linda, California, USA, lluh.org.
  • Palo Alto Medical Foundation, Sutter Health, Palo Alto, California, USA, sutterhealth.org.

ORCID-Profile: Darren Wijaya

Zitieren

APA

Wijaya, D., Hanson, Z., Lau, E. K., & Akhtari, M. (2026). Scleromyxedema Managed With High‐Dose Intravenous Immunoglobulin and Bortezomib–Dexamethasone: A Case Report. Case Reports in Oncological Medicine, 2026(1). https://doi.org/10.1155/crom/3773160

Vancouver

Wijaya D, Hanson Z, Lau EK, Akhtari M. Scleromyxedema Managed With High‐Dose Intravenous Immunoglobulin and Bortezomib–Dexamethasone: A Case Report. Case Reports in Oncological Medicine. 2026;2026(1). doi:10.1155/crom/3773160

BibTeX
@article{Wijaya2026,
  author = {Wijaya, Darren and Hanson, Zachary and Lau, Eric K and Akhtari, Mojtaba},
  title = {Scleromyxedema Managed With High‐Dose Intravenous Immunoglobulin and Bortezomib–Dexamethasone: A Case Report},
  journal = {Case Reports in Oncological Medicine},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crom/3773160}
}
Kostenlos starten →